Abstract: This invention describes ways of obtaining nano-particulated adjuvants formed by different synthetic variants of GM3 ganglioside. Depending on the fine structure of the fatty acid in the ceramide of the synthetic GM3, said adjuvants are able to stimulate specifically and in a specialized way the humoral or cellular immune response against accompanying antigens. Particularly, this invention provides immunogenic vaccine compositions that comprise peptides, polypeptides or proteins and the aforementioned nanoparticles, which are formed through the dispersion of hydrophobic proteins of the outer membrane complex (OMC) of Neisseria meningitidis in solutions containing fully synthetic variants of the GM3 ganglioside.

Abstract: This invention relates to the field of Biotechnology and Medicine. It describes the use of vaccine compositions based on the receptor binding domain of SARS-CoV-2 virus in the treatment of patients recovered from COVID-19 and in subjects vaccinated with vaccine platforms other than subunit vaccines, who fail to develop effective protective immunity or where immunity has decreased over time and a booster with the same vaccine used in primary vaccination is not recommended. Particularly, this use is described for vaccine compositions comprising a covalent conjugate of the receptor binding domain (RBD) and a carrier protein such as tetanus toxoid, diphtheria toxoid and diphtheria toxoid mutant CRM197, vaccine compositions having the RBD as antigen, with or without the immunopotentiator outer membrane vesicles of serogroup B Neisseria meningitidis.

Abstract: This invention pertains to biotechnology, more specifically to the field of human health. This document describes in particular conjugates of the SARS-CoV-2 receptor binding domain covalently conjugated to a carrier protein, the method used to obtain them, and the vaccine compositions that contain them. The vaccine compositions described in this invention are useful for the prevention of the SARS-CoV-2 infection as they induce a strong response of neutralizing antibodies.

Abstract: This invention describes ways of obtaining nano-particulated adjuvants formed by different synthetic variants of GM3 ganglioside. Depending on the fine structure of the fatty acid in the ceramide of the synthetic GM3, said adjuvants are able to stimulate specifically and in a specialized way the humoral or cellular immune response against accompanying antigens. Particularly, this invention provides immunogenic vaccine compositions that comprise peptides, polypeptides or proteins and the aforementioned nanoparticles, which are formed through the dispersion of hydrophobic proteins of the outer membrane complex (OMC) of Neisseria meningitidis in solutions containing fully synthetic variants of the GM3 ganglioside.

Abstract: This invention is related to biotechnology; in particular, to the field of human health. The described vaccine compositions induce a neutralizing immune response against the SARS-CoV-2 virus. These compositions include a portion of the receptor binding protein of the SARS-Cov-2 virus, as antigen, outer-membrane vesicles of the Neisseria meningitides group B bacteria, as immunopotentiating component, and an adjuvant. The vaccine compositions that are described in this invention are useful in the prevention of infection with the SARS-CoV-2 virus.

Abstract: This invention describes ways of obtaining nano-particulated adjuvants formed by different synthetic variants of GM3 ganglioside. Depending on the fine structure of the fatty acid in the ceramide of the synthetic GM3, said adjuvants are able to stimulate specifically and in a specialized way the humoral or cellular immune response against accompanying antigens. Particularly, this invention provides immunogenic vaccine compositions that comprise peptides, polypeptides or proteins and the aforementioned nanoparticles, which are formed through the dispersion of hydrophobic proteins of the outer membrane complex (OMC) of Neisseria meningitidis in solutions containing fully synthetic variants of the GM3 ganglioside.

Abstract: The present invention relates to the field of the Medicine, in particular with the chemical synthesis of oligosaccharide mixtures derived of ribose-ribitol-phosphate, which are used as active principle in vaccines for the prevention of infections caused by Haemophilus influenzae type b (Hib), as well as with the vaccines containing said oligosaccharide mixtures. The oligasaccharide mixtures obtained by chemical synthesis of the present invention, comprise repeating units of formulae (phosphate-ribosa-ribitol)n or (ribose-ribitol-phosphate)n of at least 5 compounds of structure A or B, which represent the repeating unit of the capsular polysaccharide of Haemophilus influenzae type b and differ only by n, being n a value contained between 4 and 25 (n≧4 y≦25), and wherein R1 or R2 is a spacer for conjugation to a carrier, with the condition of R1=spacer if R2=H, or R2=spacer if R1=H.